Cogprints

Tamsulosin � turn a round

Praveen R, Int J Cur Bio Med Sci. (2011) Tamsulosin � turn a round. [Journal (Paginated)]

Full text available as:

[img]
Preview
PDF (Tamsulosin � turn a round) - Published Version
Available under License Creative Commons Attribution No Derivatives.

479Kb

Abstract

Tamsulosin is a sulfamoylphen-ethylamine derivative, a potent and a selective antagonist of Alpha-1A adrenoceptor. It�s approved in the treatment of LUTS in BPH disease, being a specific Alpha -1A blocker it does not interfere much with the cardiovascular system. Though an age old molecule but still it�s a friendly drug to most of the physicians. Even the recent studies found its as efficacious to some of the newer molecules in the group.

Item Type:Journal (Paginated)
Keywords:Tamsulosin, Alpha, Adrenoceptor
Subjects:JOURNALS
ID Code:7319
Deposited By:CurrentSciDirect Publications, International Journal of Current Biological and Medical Science (IJCBMS)
Deposited On:02 May 2011 16:52
Last Modified:02 May 2011 16:52

References in Article

Select the SEEK icon to attempt to find the referenced article. If it does not appear to be in cogprints you will be forwarded to the paracite service. Poorly formated references will probably not work.

[1] Hieble JP, Bylund DB, Clarke DE. International union of pharmacology X. Recommendation for nomenclature of alpha-adrenoceptors: consensus update. J Pharmacol Rev 1994;47:267-270.

[2] Roosen A, James B, Wood D, Fry C. Clinical and experimental aspects of Adreno-muscarinic synergy in the bladder base and prostate.2009;28(8):938-943.

[3] Price DT, Schwinn DA, Lomasney JW. Identification, quantification, and localization of mRNA for three distinct alpha-1 adrenergic receptor subtypes in human prostate.J Urol 1993;150:546-551

[4] Holtgrewe HL. Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 1998;51:1-7.

[5] Andersson KE. Mode of action of alpha-adrenoreceptor antagonists in the treatment of lower urinary tract symptoms. BJU 2000;85:12-18.

[6] Puppo P. Do we know everything about alpha-blockade in the management of lower urinary tract symptoms?.J Eur Urol 2001;39:38-41.

[7] Schwinn DA, Michelotti GA. alpha-Adrenergic receptors in the lower urinary tract and vascular bed: potential role for the alpha subtype in filling symptoms and effects of ageing on vascular expression. BJU 2000;85:6-11.

[8] Khoury S, Cockett A, Aso Y. International consultation on urological diseases: a decade of progress. J Prostate 2000;45:194-199

[9] Puppo P. Do we know everything about alpha-blockade in the management of lower urinary tract symptoms?. Eur Urol 2001 Jan; 39 Suppl. 2.: 38-41

[10] Beduschi MC, Beduschi R, Oesterling JE. Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist. Urology 1998; 51: 861-72

[11] de Mey C, Michel MC, McEwen J, et al. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol 1998; 33: 481-8

[12] van Hoogdalem EJ, Soeishi Y, Matsushima H, et al. Disposition of the selective [alpha]1A-adrenoceptor antagonist tamsulosin in humans: comparison with data from interspecies scaling. J Pharm Sci 1997; 86: 1156-61

[13] Boehringer Ingelheim Pharmaceuticals Incorporated. Flomax (tamsulosin) prescribing information. 2000.

[14] Salinas F, Gabriela, Rosette J, Michel, Martin C. Pharmacokinetics and Pharmacodynamics of Tamsulosin in its Modified-Release and Oral Controlled Absorption System Formulations. 2010;49(3):177-88.

[15] Kawachi Y, Sakurai T, Sugimura S, Iwata S, Noto K, Honda S et al. Long-term treatment and prognostic factors of α1-blockers for lower urinary tract symptoms associated with benign prostatic hyperplasia: A pilot study comparing naftopidil and tamsulosin hydrochloride.2010;44:38-45.

[16] Yamanouchi Pharmaceutical Co. Ltd. Harnal (tamsulosin) prescribing information. 2000

Metadata

Repository Staff Only: item control page